With the purpose to increase our knowledge about the spectrum of therapeutic action of itraconazole, the activity of a new triazolic derivative against Toxoplasma gondii was studied in vivo and in vitro with the aid of an experimental infection model in mice. The trial also aimed at a possible improvement of the therapy of toxoplasmosis in regard to safety and dosing easiness. The present study has not shown significant activity of itraconazole against Toxoplasma gondii, differing from a previous observation that showed it's activity against Trypanosoma cruzi.